Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation

被引:284
作者
Caira, FC
Stock, SR
Gleason, TG
McGee, EC
Huang, J
Bonow, RO
Spelsberg, TC
McCarthy, PM
Rahimtoola, SH
Rajamannan, NM
机构
[1] Northwestern Univ, Feinberg Sch Med, Div Cardiol & Cardiothorac Surg, Chicago, IL 60611 USA
[2] Northwestern Univ, Inst Bioengn & Nanosci Adv Med, Chicago, IL 60611 USA
[3] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA
[4] Mayo Clin Rochester, Coll Med, Dept Mol Biol & Biochem, Rochester, MN USA
[5] Univ So Calif, Keck Sch Med, Div Cardiovasc Med, Dept Med,LAC, Los Angeles, CA 90089 USA
[6] Univ So Calif, Keck Sch Med, USC, Med Ctr, Los Angeles, CA 90089 USA
关键词
D O I
10.1016/j.jacc.2006.02.040
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES The goal of this research was to define the cellular mechanisms involved in myxomatous mitral valve disease and calcific aortic valve disease and to redefine the term degenerative valve disease in terms of an active cellular biology. BACKGROUND "Degenerative" valvular heart disease is the primary cause of regurgitant and stenotic valvular lesion in the U.S. However, the signaling pathways are not known. We hypothesize that valve degeneration occurs due to an osteoblastic differentiation process mediated by the low-density lipoprotein receptor-related protein 5 (Lrp5) signaling pathway to cause valve thickening. METHODS We examined human diseased valves: myxomatous mitral valves (n = 23), calcified tricuspid aortic valves (n = 27), calcified bicuspid aortic valves (n = 23), and control tissue from mitral and aortic valves (n = 40). The valves were examined by reverse transcriptase-polymerase chain reaction, Western blot, and immunohistochemistry for signaling markers important in osteoblast differentiation: Sox9 and Cbfa1 (transcription factors for osteoblast differentiation); Lrp5 and Wnt3 (osteoblast differentiation signaling marker), osteopontin and osteocalcin (osteoblast endochrondral bone matrix proteins), and proliferating cell nuclear antigen (a marker of cell proliferation). Cartilage development and bone formation was measured by Alcian blue stain and Alizarin red stain. Computed Scano MicroCT-40 (Bassersdorf, Switzerland) analysis measured calcium burden. RESULTS Low-density lipoprotein receptor-related protein 5, osteocalcin, and other osteochrondrogenic differentiation markers were increased in the calcified aortic valves by protein and gene expression (p > 0.001). Sox9, Lrp5 receptor, and osteocalcin were increased in myxomatous mitral valves by protein and gene expression (p > 0.001). MicroCT was positive in the calcified aortic valves and negative in the myxomatous mitral valves. CONCLUSIONS The mechanism of valvular heart disease involves an endochondral bone process that is expressed as cartilage in the mitral valves and bone in the aortic valves. Up-regulation of the Lrp5 pathway may play a role in the mechanism for valvular heart disease.
引用
收藏
页码:1707 / 1712
页数:6
相关论文
共 16 条
[1]   Apparently normal mitral valves in patients with heart failure demonstrate biochemical and structural derangements - An extracellular matrix and echocardiographic study [J].
Grande-Allen, KJ ;
Borowski, AG ;
Troughton, RW ;
Houghtaling, PL ;
DiPaola, NR ;
Moravec, CS ;
Vesely, I ;
Griffin, BP .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (01) :54-61
[2]   Glycosaminoglycans and proteoglycans in normal mitral valve leaflets and chordae: association with regions of tensile and compressive loading [J].
Grande-Allen, KJ ;
Calabro, A ;
Gupta, V ;
Wight, TN ;
Hascall, VC ;
Vesely, I .
GLYCOBIOLOGY, 2004, 14 (07) :621-633
[3]   THE CDNA CLONING AND RNA DISTRIBUTION OF BOVINE OSTEOPONTIN [J].
KERR, JM ;
FISHER, LW ;
TERMINE, JD ;
YOUNG, MF .
GENE, 1991, 108 (02) :237-243
[4]   THE HUMAN BONE SIALOPROTEIN GENE (IBSP) - GENOMIC LOCALIZATION AND CHARACTERIZATION [J].
KERR, JM ;
FISHER, LW ;
TERMINE, JD ;
WANG, MG ;
MCBRIDE, OW ;
YOUNG, MF .
GENOMICS, 1993, 17 (02) :408-415
[5]   Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve [J].
Makkena, B ;
Salti, H ;
Subramaniam, M ;
Thennapan, S ;
Bonow, RH ;
Caira, F ;
Bonow, RO ;
Spelsberg, TC ;
Rajamannan, NM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (04) :631-633
[6]   Bone formation and inflammation in cardiac valves [J].
Mohler, ER ;
Gannon, F ;
Reynolds, C ;
Zimmerman, R ;
Keane, MG ;
Kaplan, FS .
CIRCULATION, 2001, 103 (11) :1522-1528
[7]   OSTEOPONTIN IS EXPRESSED IN HUMAN AORTIC VALVULAR LESIONS [J].
OBRIEN, KD ;
KUUSISTO, J ;
REICHENBACH, DD ;
FERGUSON, M ;
GIACHELLI, C ;
ALPERS, CE ;
OTTO, CM .
CIRCULATION, 1995, 92 (08) :2163-2168
[8]   Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves [J].
Rabkin, E ;
Aikawa, M ;
Stone, JR ;
Fukumoto, Y ;
Libby, P ;
Schoen, FJ .
CIRCULATION, 2001, 104 (21) :2525-2532
[9]   Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway [J].
Rajamannan, NM ;
Subramaniam, M ;
Caira, F ;
Stock, SR ;
Spelsberg, TC .
CIRCULATION, 2005, 112 (09) :I229-I234
[10]   Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve [J].
Rajamannan, NM ;
Subramaniam, M ;
Stock, SR ;
Stone, NJ ;
Springett, M ;
Ignatiev, KI ;
McConnell, JP ;
Singh, RJ ;
Bonow, RO ;
Spelsberg, TC .
HEART, 2005, 91 (06) :806-810